AMGN vs. GEHC: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at AMGN and GEHC, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Overview
AMGN’s market capitalization of 160.37 billion USD is substantially larger than GEHC’s 34.83 billion USD, indicating a significant difference in their market valuations.
GEHC carries a higher beta at 1.29, indicating it’s more sensitive to market moves, while AMGN (beta: 0.50) exhibits greater stability.
| Symbol | AMGN | GEHC |
|---|---|---|
| Company Name | Amgen Inc. | GE HealthCare Technologies Inc. |
| Country | US | US |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers - General | Medical - Healthcare Information Services |
| CEO | Robert A. Bradway | Peter J. Arduini |
| Price | 298.24 USD | 76.07 USD |
| Market Cap | 160.37 billion USD | 34.83 billion USD |
| Beta | 0.50 | 1.29 |
| Exchange | NASDAQ | NASDAQ |
| IPO Date | June 17, 1983 | December 15, 2022 |
| ADR | No | No |
Historical Performance
This chart compares the performance of AMGN and GEHC by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period.
Data is adjusted for dividends and splits.
Profitability
Return on Equity
AMGN
92.94%
Drug Manufacturers - General Industry
- Max
- 95.59%
- Q3
- 76.92%
- Median
- 30.71%
- Q1
- 8.97%
- Min
- -14.85%
In the upper quartile for the Drug Manufacturers - General industry, AMGN’s Return on Equity of 92.94% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
GEHC
25.87%
Medical - Healthcare Information Services Industry
- Max
- 25.87%
- Q3
- 8.12%
- Median
- 2.99%
- Q1
- -18.32%
- Min
- -48.18%
In the upper quartile for the Medical - Healthcare Information Services industry, GEHC’s Return on Equity of 25.87% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Return on Invested Capital
AMGN
9.53%
Drug Manufacturers - General Industry
- Max
- 25.72%
- Q3
- 17.89%
- Median
- 11.47%
- Q1
- 9.39%
- Min
- 2.87%
AMGN’s Return on Invested Capital of 9.53% is in line with the norm for the Drug Manufacturers - General industry, reflecting a standard level of efficiency in generating profits from its capital base.
GEHC
8.77%
Medical - Healthcare Information Services Industry
- Max
- 26.81%
- Q3
- 8.81%
- Median
- 2.09%
- Q1
- -11.56%
- Min
- -32.60%
GEHC’s Return on Invested Capital of 8.77% is in line with the norm for the Medical - Healthcare Information Services industry, reflecting a standard level of efficiency in generating profits from its capital base.
Net Profit Margin
AMGN
17.39%
Drug Manufacturers - General Industry
- Max
- 34.51%
- Q3
- 23.04%
- Median
- 14.73%
- Q1
- 11.78%
- Min
- 2.18%
AMGN’s Net Profit Margin of 17.39% is aligned with the median group of its peers in the Drug Manufacturers - General industry. This indicates its ability to convert revenue into profit is typical for the sector.
GEHC
11.03%
Medical - Healthcare Information Services Industry
- Max
- 39.13%
- Q3
- 9.34%
- Median
- 1.37%
- Q1
- -15.05%
- Min
- -39.66%
A Net Profit Margin of 11.03% places GEHC in the upper quartile for the Medical - Healthcare Information Services industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin
AMGN
21.82%
Drug Manufacturers - General Industry
- Max
- 40.70%
- Q3
- 28.90%
- Median
- 23.41%
- Q1
- 19.05%
- Min
- 16.13%
AMGN’s Operating Profit Margin of 21.82% is around the midpoint for the Drug Manufacturers - General industry, indicating that its efficiency in managing core business operations is typical for the sector.
GEHC
13.99%
Medical - Healthcare Information Services Industry
- Max
- 39.94%
- Q3
- 11.27%
- Median
- 3.94%
- Q1
- -9.81%
- Min
- -29.30%
An Operating Profit Margin of 13.99% places GEHC in the upper quartile for the Medical - Healthcare Information Services industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | AMGN | GEHC |
|---|---|---|
| Return on Equity (TTM) | 92.94% | 25.87% |
| Return on Assets (TTM) | 6.64% | 6.50% |
| Return on Invested Capital (TTM) | 9.53% | 8.77% |
| Net Profit Margin (TTM) | 17.39% | 11.03% |
| Operating Profit Margin (TTM) | 21.82% | 13.99% |
| Gross Profit Margin (TTM) | 63.00% | 41.96% |
Financial Strength
Current Ratio
AMGN
1.17
Drug Manufacturers - General Industry
- Max
- 1.67
- Q3
- 1.37
- Median
- 1.26
- Q1
- 0.87
- Min
- 0.39
AMGN’s Current Ratio of 1.17 aligns with the median group of the Drug Manufacturers - General industry, indicating that its short-term liquidity is in line with its sector peers.
GEHC
0.98
Medical - Healthcare Information Services Industry
- Max
- 5.37
- Q3
- 3.30
- Median
- 1.91
- Q1
- 1.37
- Min
- 0.54
GEHC’s Current Ratio of 0.98 falls into the lower quartile for the Medical - Healthcare Information Services industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio
AMGN
9.24
Drug Manufacturers - General Industry
- Max
- 2.95
- Q3
- 2.44
- Median
- 0.86
- Q1
- 0.68
- Min
- 0.09
With a Debt-to-Equity Ratio of 9.24, AMGN operates with exceptionally high leverage compared to the Drug Manufacturers - General industry norm. This suggests an aggressive reliance on debt financing, which can magnify returns but also significantly elevates financial risk.
GEHC
1.00
Medical - Healthcare Information Services Industry
- Max
- 1.14
- Q3
- 0.65
- Median
- 0.16
- Q1
- 0.04
- Min
- 0.00
GEHC’s leverage is in the upper quartile of the Medical - Healthcare Information Services industry, with a Debt-to-Equity Ratio of 1.00. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio
AMGN
3.19
Drug Manufacturers - General Industry
- Max
- 27.46
- Q3
- 14.40
- Median
- 7.80
- Q1
- 4.07
- Min
- 1.67
In the lower quartile for the Drug Manufacturers - General industry, AMGN’s Interest Coverage Ratio of 3.19 indicates a tighter cushion for servicing debt, suggesting less financial flexibility than many of its competitors.
GEHC
5.73
Medical - Healthcare Information Services Industry
- Max
- 12.12
- Q3
- 3.11
- Median
- 1.20
- Q1
- -12.03
- Min
- -25.76
GEHC’s Interest Coverage Ratio of 5.73 is in the upper quartile for the Medical - Healthcare Information Services industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
Financial Strength at a Glance
| Symbol | AMGN | GEHC |
|---|---|---|
| Current Ratio (TTM) | 1.17 | 0.98 |
| Quick Ratio (TTM) | 0.88 | 0.76 |
| Debt-to-Equity Ratio (TTM) | 9.24 | 1.00 |
| Debt-to-Asset Ratio (TTM) | 0.64 | 0.27 |
| Net Debt-to-EBITDA Ratio (TTM) | 3.92 | 1.92 |
| Interest Coverage Ratio (TTM) | 3.19 | 5.73 |
Growth
The following charts compare key year-over-year (YoY) growth metrics for AMGN and GEHC. These metrics are based on the companies’ annual financial reports.
Revenue Growth
Earnings Per Share (EPS) Growth
Free Cash Flow Growth
Dividend
Dividend Yield
AMGN
3.10%
Drug Manufacturers - General Industry
- Max
- 8.72%
- Q3
- 4.10%
- Median
- 3.34%
- Q1
- 1.89%
- Min
- 0.00%
AMGN’s Dividend Yield of 3.10% is consistent with its peers in the Drug Manufacturers - General industry, providing a dividend return that is standard for its sector.
GEHC
0.17%
Medical - Healthcare Information Services Industry
- Max
- 7.19%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
With a Dividend Yield of 0.17%, GEHC offers a more attractive income stream than most of its peers in the Medical - Healthcare Information Services industry, signaling a strong commitment to shareholder returns.
Dividend Payout Ratio
AMGN
82.64%
Drug Manufacturers - General Industry
- Max
- 266.46%
- Q3
- 78.91%
- Median
- 60.27%
- Q1
- 43.74%
- Min
- 0.00%
AMGN’s Dividend Payout Ratio of 82.64% is in the upper quartile for the Drug Manufacturers - General industry. This indicates a strong commitment to shareholder returns but also suggests that a smaller portion of earnings is retained for reinvestment compared to many peers.
GEHC
2.61%
Medical - Healthcare Information Services Industry
- Max
- 130.89%
- Q3
- 2.61%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
GEHC’s Dividend Payout Ratio of 2.61% is within the typical range for the Medical - Healthcare Information Services industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
Dividend at a Glance
| Symbol | AMGN | GEHC |
|---|---|---|
| Dividend Yield (TTM) | 3.10% | 0.17% |
| Dividend Payout Ratio (TTM) | 82.64% | 2.61% |
Valuation
Price-to-Earnings Ratio
AMGN
27.04
Drug Manufacturers - General Industry
- Max
- 27.96
- Q3
- 25.84
- Median
- 18.32
- Q1
- 16.65
- Min
- 3.39
A P/E Ratio of 27.04 places AMGN in the upper quartile for the Drug Manufacturers - General industry. This high valuation relative to peers suggests the market holds elevated expectations for the company’s future growth.
GEHC
15.92
Medical - Healthcare Information Services Industry
- Max
- 114.57
- Q3
- 67.12
- Median
- 45.42
- Q1
- 28.19
- Min
- 6.48
In the lower quartile for the Medical - Healthcare Information Services industry, GEHC’s P/E Ratio of 15.92 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
Forward P/E to Growth Ratio
AMGN
7.57
Drug Manufacturers - General Industry
- Max
- 3.10
- Q3
- 3.09
- Median
- 2.72
- Q1
- 2.18
- Min
- 1.02
AMGN’s Forward PEG Ratio of 7.57 is exceptionally high for the Drug Manufacturers - General industry. This suggests its stock price is very high relative to its expected earnings growth, signaling significant overvaluation risk.
GEHC
1.22
Medical - Healthcare Information Services Industry
- Max
- 6.35
- Q3
- 2.93
- Median
- 2.00
- Q1
- 0.55
- Min
- 0.03
GEHC’s Forward PEG Ratio of 1.22 is within the middle range of its peers in the Medical - Healthcare Information Services industry. This suggests a reasonable balance between the stock’s price and its expected growth, aligning with sector valuation norms.
Price-to-Sales Ratio
AMGN
4.70
Drug Manufacturers - General Industry
- Max
- 6.47
- Q3
- 4.47
- Median
- 3.53
- Q1
- 1.96
- Min
- 0.41
AMGN’s P/S Ratio of 4.70 is in the upper echelon for the Drug Manufacturers - General industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
GEHC
1.76
Medical - Healthcare Information Services Industry
- Max
- 10.90
- Q3
- 5.95
- Median
- 2.46
- Q1
- 1.42
- Min
- 0.36
GEHC’s P/S Ratio of 1.76 aligns with the market consensus for the Medical - Healthcare Information Services industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio
AMGN
25.85
Drug Manufacturers - General Industry
- Max
- 7.80
- Q3
- 7.80
- Median
- 5.30
- Q1
- 4.06
- Min
- 1.08
The P/B Ratio is often not a primary valuation metric for the Drug Manufacturers - General industry.
GEHC
3.78
Medical - Healthcare Information Services Industry
- Max
- 12.91
- Q3
- 6.69
- Median
- 2.84
- Q1
- 1.88
- Min
- 1.03
The P/B Ratio is often not a primary valuation metric for the Medical - Healthcare Information Services industry.
Valuation at a Glance
| Symbol | AMGN | GEHC |
|---|---|---|
| Price-to-Earnings Ratio (P/E, TTM) | 27.04 | 15.92 |
| Forward PEG Ratio (TTM) | 7.57 | 1.22 |
| Price-to-Sales Ratio (P/S, TTM) | 4.70 | 1.76 |
| Price-to-Book Ratio (P/B, TTM) | 25.85 | 3.78 |
| Price-to-Free Cash Flow Ratio (P/FCF, TTM) | 14.69 | 25.35 |
| EV-to-EBITDA (TTM) | 16.88 | 11.84 |
| EV-to-Sales (TTM) | 6.12 | 2.10 |